{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:05:31Z","timestamp":1749873931385,"version":"3.41.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"the National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-004"],"award-info":[{"award-number":["2022-PUMCH-C-004"]}]},{"name":"the National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-002"],"award-info":[{"award-number":["2022-PUMCH-D-002"]}]},{"name":"the National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-009"],"award-info":[{"award-number":["2022-PUMCH-B-009"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2021-I2M-1-016"],"award-info":[{"award-number":["2021-I2M-1-016"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272046"],"award-info":[{"award-number":["82272046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["3332023124"],"award-info":[{"award-number":["3332023124"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["3332024114"],"award-info":[{"award-number":["3332024114"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Accurate diagnosis of bone metastases in prostate cancer is essential for staging, prognosis, and treatment. Although PSMA PET\/CT is highly effective, complementary imaging is needed to clarify indeterminate lesions. The novel bisphosphonate-based agent [<jats:sup>68<\/jats:sup>Ga]Ga-P15-041 shows superior diagnostic accuracy over conventional SPECT imaging, indicating its potential as an auxiliary diagnostic tool. This study explores its role in detecting and assessing prostate cancer bone metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>This prospective study enrolled 35 patients with prostate cancer and skeletal metastases, who underwent both [<jats:sup>68<\/jats:sup>Ga]Ga-P15-041 and [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT within 1 week. Lesions detected by [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT were classified using Prostate-specific Membrane Antigen Reporting and Data System 2.0.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>[<jats:sup>68<\/jats:sup>Ga]Ga-P15-041 PET\/CT detected more lesions than [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT (525 vs 509, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and demonstrated significantly higher tracer uptake, with a mean SUV of 20.73 \u00b1 14.67 compared with 11.13 \u00b1 8.12 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). It detected significantly more osteoblastic lesions (504 vs 391, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). In addition, this study established the Reporting and Data System for [<jats:sup>68<\/jats:sup>Ga]Ga-P15-041 (P15-041-RADS), which classifies prostate cancer bone metastases into 5 categories based on SUV<jats:sub>max<\/jats:sub> and morphologic changes. P15-041-RADS reclassified 85.71% of Prostate-specific Membrane Antigen Reporting and Data System category 3 lesions and 95.00% of 5T lesions into higher-confidence categories, offering improved diagnostic clarity. Limitations include small sample size and lack of pathologic gold standards.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>[<jats:sup>68<\/jats:sup>Ga]Ga-P15-041 PET\/CT is a promising and accessible bone imaging agent that could complement [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT in the diagnosis and classification of bone metastases in prostate cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005883","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T05:00:17Z","timestamp":1746421217000},"page":"517-522","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonate Bone Imaging Agent [68Ga]Ga-P15-041 for Evaluating Skeletal Metastases in Prostate Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Jiarou","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases"},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases"},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianrui","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-2441","authenticated-orcid":false,"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases"},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases"},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-1136","authenticated-orcid":false,"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases"},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8531","authenticated-orcid":false,"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University, Ministry of Education, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-8049","authenticated-orcid":false,"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weigang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-850X","authenticated-orcid":false,"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases"},{"name":"Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"JNCI J Natl Cancer Inst"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific (18)F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer","volume":"64","author":"Seifert","year":"2023","journal-title":"J Nucl Med"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ph10030068","article-title":"Assessment of bone metastases in patients with prostate cancer\u2014a comparison between (99m)Tc-bone-scintigraphy and [(68)Ga]Ga-PSMA PET\/CT","volume":"10","author":"Thomas","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/RLU.0000000000000594","article-title":"Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET\/CT","volume":"40","author":"Chakraborty","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-016-3469-3","article-title":"Evaluation of bone-seeking novel radiotracer (68)Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast","volume":"44","author":"Passah","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00259-009-1355-y","article-title":"PET\/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study","volume":"37","author":"Fellner","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12149-019-01348-7","article-title":"Preliminary results of biodistribution and dosimetric analysis of [(68)Ga]Ga-DOTA(ZOL): a new zoledronate-based bisphosphonate for PET\/CT diagnosis of bone diseases","volume":"33","author":"Khawar","year":"2019","journal-title":"Ann Nucl Med"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/acs.molpharmaceut.0c00103","article-title":"A New [(68)Ga]Ga-HBED-CC-Bisphosphonate as a Bone Imaging Agent","volume":"17","author":"Zha","year":"2020","journal-title":"Mol Pharm"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2020.04.002","article-title":"Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [(68)Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies","volume":"86-87","author":"Doot","year":"2020","journal-title":"Nucl Med Biol"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"109485","DOI":"10.1016\/j.apradiso.2020.109485","article-title":"Development and validation of a kit formulation of [(68)Ga]Ga-P15-041 as a bone imaging agent","volume":"169","author":"Hong","year":"2021","journal-title":"Appl Radiat Isot"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"766851","DOI":"10.3389\/fonc.2021.766851","article-title":"(68)Ga-P15-041, a novel bone imaging agent for diagnosis of bone metastases","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00259-018-4048-6","article-title":"Comparison of [(68)Ga]Ga-PSMA-11 PET\/CT with [(18)F]NaF PET\/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy","volume":"45","author":"Uprimny","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/cpf.12480","article-title":"(68) Ga-PSMA PET\/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature","volume":"38","author":"Zacho","year":"2018","journal-title":"Clin Physiol Funct Imaging"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00259-018-3936-0","article-title":"68Ga-PSMA PET\/CT in the evaluation of bone metastases in prostate cancer","volume":"45","author":"Sachpekidis","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11307-017-1101-y","article-title":"[68Ga]PSMA-HBED-CC uptake in osteolytic, osteoblastic, and bone marrow metastases of prostate cancer patients","volume":"19","author":"Janssen","year":"2017","journal-title":"Mol Imag Biol"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00259-020-04867-y","article-title":"A prospective intra-individual comparison of [(68)Ga]Ga-PSMA-11 PET\/CT, [(68)Ga]Ga-NODAGA(ZOL) PET\/CT, and [(99m)Tc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases","volume":"48","author":"Lawal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1021\/acs.jmedchem.3c01294","article-title":"Lu-177-labeled hetero-bivalent agents targeting PSMA and bone metastases for radionuclide therapy","volume":"66","author":"Zha","year":"2023","journal-title":"J Med Chem"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:44Z","timestamp":1749816044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005883"}},"subtitle":["A Comparison With [68Ga]Ga-PSMA-11 PET\/CT"],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005883","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"2024-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}